Insulin aspart
Also known as: NovoRapid · NovoMix · Fiasp · Insulin aspart Sanofi · Kirsty (previously Kixelle) · Dazparda · .Insulin Aspart Protamine and Insulin Aspart · Insulin Aspart Protamine and Insulin Aspart Mix 70/30 · NOVOLOG · NovoLog Mix 70/30
General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).
In short
In the European Union, insulin aspart is indicated for the treatment of diabetes mellitus, with specific products approved for adults, adolescents, and children aged 1 year and above. In the United States, a mixture of insulin aspart protamine and insulin aspart is indicated to improve glycemic control in adult patients with diabetes mellitus. This mixture is not for use in the treatment of diabetic ketoacidosis, and its fixed proportions of rapid-acting and long-acting insulins do not allow for basal versus prandial dose adjustments.
From: Source: European Medicines Agency (EMA), Fiasp — EPAR, 23/09/2021. © European Medicines Agency. · Source: European Medicines Agency (EMA), NovoMix — EPAR, 29/08/2023. © European Medicines Agency. · Source: European Medicines Agency (EMA), NovoRapid — EPAR, 28/05/2025. © European Medicines Agency. · Data provided by the U.S. Food and Drug Administration.
AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.
Codes
- RxNorm
- 51428 insulin aspart, human
- EMA
- EMEA/H/C/000258, EMEA/H/C/000308, EMEA/H/C/004046, EMEA/H/C/005033, EMEA/H/C/004965, EMEA/H/C/006187
Official indications
Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.
EMA (EU) Fiasp
Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Source: European Medicines Agency (EMA), Fiasp — EPAR, 23/09/2021. © European Medicines Agency.
Document date: 23/09/2021 · Official document →
FDA (USA) NovoLog Mix 70/30
1 INDICATIONS AND USAGE NOVOLOG MIX 70/30 is a mixture of insulin aspart protamine and insulin aspart indicated to improve glycemic control in adult patients with diabetes mellitus. Limitations of Use: NOVOLOG MIX 70/30 is not recommended for the treatment of diabetic ketoacidosis. The proportions of rapid-acting and long-acting insulins in NOVOLOG MIX 70/30 are fixed and do not allow for basal versus prandial dose adjustments. NOVOLOG MIX 70/30 is a mixture of insulin aspart protamine, an intermediate-acting human insulin analog, and insulin aspart, a rapid-acting human insulin analog, indicated to improve glycemic control in adult patients with diabetes mellitus. Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis. The proportions of rapid-acting and long-acting insulins are fixed and do not allow for basal versus prandial dose adjustments (1) .
Data provided by the U.S. Food and Drug Administration.
Document date: 20260518 · Official document →
EMA (EU) NovoMix
Treatment of diabetes mellitus.
Source: European Medicines Agency (EMA), NovoMix — EPAR, 29/08/2023. © European Medicines Agency.
Document date: 29/08/2023 · Official document →
EMA (EU) NovoRapid
NovoRapid is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Source: European Medicines Agency (EMA), NovoRapid — EPAR, 28/05/2025. © European Medicines Agency.
Document date: 28/05/2025 · Official document →
Other treatments A–Z
What people report
Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.
External resources
Questions
What is Insulin aspart approved for in the European Union?
Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. (Source: European Medicines Agency (EMA), Fiasp — EPAR, 23/09/2021. © European Medicines Agency.)
Sources and attribution
- Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
- Data provided by the U.S. Food and Drug Administration.
- Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
- This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
- Source: European Medicines Agency (EMA), Fiasp — EPAR, 23/09/2021. © European Medicines Agency.
- Source: European Medicines Agency (EMA), NovoMix — EPAR, 29/08/2023. © European Medicines Agency.
- Source: European Medicines Agency (EMA), NovoRapid — EPAR, 28/05/2025. © European Medicines Agency.
Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →
About this page. This page brings together public information from official sources, each cited where it is used. It is not medical advice, it is not a diagnosis, and it does not tell you which treatment to take.
Treatments. Indications are quoted unchanged from official product information (European Medicines Agency, U.S. Food and Drug Administration). They describe what a medicine is approved for, not whether it is right for you. Approved uses can differ between countries. Always read the package leaflet and follow your doctor's or pharmacist's advice.
What people report. Figures marked "reported by Anpheros users" are anonymous counts from at least 20 people who agreed to share them. They show what people report, not what works, and they are not clinical evidence.
Links between terms. "May be associated with" means the link appears in a cited source. It does not mean you have that condition.
In an emergency, call 112 (or your local emergency number). Do not delay seeking medical help because of something you read here.